Apimeds Pharmaceuticals US (APUS) - מזומנים למניה

Apimeds Pharmaceuticals US - לוגו גרפי של המנפיק APUS

Apimeds Pharmaceuticals (APUS) develops unique anti-inflammatory agents derived from bee venom as it seeks FDA approval. However, external political tensions and patent disputes are complicating its international expansion. Technological progress is driven by the automated analysis of biomaterials. The cash per share history demonstrates financial resilience, with the current value standing at 4.34, which serves as a defensive buffer for the company.

APUS (Apimeds Pharmaceuticals US) היסטוריית מזומנים למניה מ-10.05.2025 עד 20.11.2026

פילוחי מדדים מקיפים ואנליטיקה עבור Apimeds Pharmaceuticals, Inc. (APUS)

- מדדי זמינות כספים ותזרימי מזומנים:
ניתוח מסכם של החברה:Apimeds Pharmaceuticals, Inc. APUS
מוצר ממותג של Apimeds Pharmaceuticals US

Cash per share measures the volume of liquid reserves available for settling obligations or reinvestment. An increase in this metric confirms financial stability, while a decrease signals capital depletion. By analyzing changes in the cash position per share, an investor assesses the burn rate. For Apimeds Pharmaceuticals (APUS), this resource is critical for financing Apitox clinical trials. A sufficient cash reserve guarantees the scaling of biologics expansion.